Melanoma and nonmelanoma skin cancers and the immune system

Advances in Experimental Medicine and Biology

Volumn 624, Issue , 2008, Pages 187-202

  Baron, Elma D ^a,b   Domingo, Diana Santo ^c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; MELANOMA VACCINE; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; BASAL CELL CARCINOMA; CANCER INCIDENCE; CANCER SUSCEPTIBILITY; DENDRITIC CELL; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; INFLAMMATION; INNATE IMMUNITY; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN CARCINOGENESIS; SKIN CARCINOMA; SOLAR RADIATION; T LYMPHOCYTE; UNITED STATES; CELLULAR IMMUNITY; IMMUNOLOGY; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; ULTRAVIOLET RADIATION;

CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; HUMANS; IMMUNE SYSTEM; IMMUNITY, CELLULAR; INFLAMMATION; MELANOMA; SKIN NEOPLASMS; ULTRAVIOLET RAYS;

EID: 42949134377     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-77574-6_15     Document Type: Review

References (149)

1. Burnet M. Concepts of autoimmune disease and their implications for therapy. Perspect Biol Med 1967 Winter; 10(2):14M51.
2. Pardoll DM. Immunology. Stress, NK receptors and immune surveillance. Science 2001; 294(5542):534-536.
3. Dunn GP, Old LJ, Schreiber RX). The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21(2): 137-148.
4. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003; 21:807-839.
5. Nagai H, Horikawa T, Hara I et al. In vivo elimination of CD25 regulatory T-cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Exp Dermatol 2004; 13(10):613-620.
6. Han J, Colditz GA, Hunter DJ. Risk factors for skin cancers: a nested case-control study within the Nurses' Health Study. Int J Epidemiol 2006.
7. Veness MJ. Defining patients with high-risk cutaneous squamous cell carcinoma. Australas J Dermatol 2006; 47(l):28-33.
8. Jcmec GB, Holm EA. Nonmelanoma skin cancer in organ transplant patients. Transplantation 2003; 75(3):253-257.
9. Nguyen TH, Ho DQ. Nonmelanoma skin cancer. Curr Treat Options Oncol 2002; 3(3): 193-203.
10. Le Mire L, HoUowood K, Gray D et al. Melanomas in renal transplant recipients. Br J Dermatol 2006; 154(3):472-477.
11. Euvrard S, Kanitakis J, DecuUier E et aL Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation 2006; 81(8):1093-1100.
12. Boyle J, MacKie RM, Briggs JD et al. Cancer, warts and sunshine in renal transplant patients. A case-control study Lancet 1984; l(8379):702-705.
13. Tiu J, Li H, Rassekh C et al. Molecular basis of posttransplant squamous cell carcinoma: the potential role of cyclosporine a in carcinogenesis. Laryngoscope 2006; 116(5):762-769.
14. Yarosh DB, Pena AV, Nay SLV et al. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 2005; 125(5): 1020-1025.
15. O'Donovan P, Perrett CM, Zhang X et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309(5742): 1871-1874.
16. Ramsay HM, Fryer AA, Recce S et al. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am J Kidney Dis 2000; 36(1): 167-176.
17. Wilkins K, Turner R, Dolev JC et al. Cutaneous maUgnancy and human immunodeficiency virus disease. J Am Acad Dermatol 2006; 54(2): 189-206, quiz 207-10.
18. Nguyen P, Vin-Christian K, Ming ME et al. Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol 2002; 138(6):758-763.
19. Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001; 63(l-3):8-18.
20. Mclnikova VO, Ananthaswamy HN. Cellular and molecular events leading to the development of skin cancer. Mutat Res 2005; 571(1-2):9M06.
21. Yarosh DB. DNA repair, immunosuppression and skin cancer. Cutis 2004; 74(5 Suppl): 10-13.
22. Hattori Y, Nishigori C, Tanaka T et al. 8-hydroxy-2*-deoxyguanosine is increased in epidermal cells of hairless mice after chronic ultraviolet B exposure. J Invest Dermatol 1996; 107(5):733-737.
23. Zhang X, Wii RS, Fu W et al. Production of reactive oxygen species and 8-hydroxy-2'deoxyguanosine in KB cells co-exposed to benzo[a]pyrene and UV-A radiation. Chemosphere 2004; 55(10): 1303-1308.
24. Schwarz T. Mechanisms of UV-induced immunosuppression. Keio J Med 2005; 54(4):165-171.
25. Cooper KD. Cell-mediated immimosuppressive mechanisms induced by UV radiation. Photochem Photobiol 1996; 63(4):400-406.
26. Yoshikawa T, Rae V, Bruins-Slot W et al. Susceptibility to effects of UVB radiation on induction of contact hypersensitivity as a risk factor for skin cancer in humans. J Invest Dermatol 1990; 95(5):530-536.
27. Streilein JW, Taylor JR, Vincek V et al. Relationship between ultraviolet radiation-induced immunosuppression and carcinogenesis. J Invest Dermatol 1994; 103(5 Suppl):107S-lllS.
28. Rivas JM, Ullrich SE. Systemic suppression of delayed-type hypersensitivity by supernatants from UV-irradiated keratinocytes. An essential role for keratinocyte-derived IL-10. J Immunol 1992; 149(12):3865-3871.
29. Nghiem DX, Kazimi N, Mitchell DL et al. Mechanisms underlying the suppression of established immune responses by ultraviolet radiation. J Invest Dermatol 2002; 119(3):600-608.
30. Noonan FP, De Fabo EC, Kripke ML. Suppression of contact hypersensitivity by UV radiation and its relationship to UV-induced suppression of tumor immunity. Photochem Photobiol 1981; 34(6):683-689.
31. Mueller MM. Inflammation in epithelial skin tumours: old stories and new ideas. Eur J Cancer 2006; 42(6):735-744.
32. Shellman YG, Makela M, Norris DA. Induction of secreted matrix metalloproteinase-9 activity in human melanoma cells by extracellular matrix proteins and cytokines. Melanoma Res 2006; 16(3):207-211.
33. Ozawa H, Aiba S, Nakagawa et al. Interferon-gamma and interleukin-10 inhibit antigen presentation by Langerhans cells for T helper type 1 cells by suppressing their CD80 (B7-1) expression. Eur J Immunol 1996; 26(3):648-652.
34. Hill LL, Shreedhar VK, Kripke ML et al. A critical role for Fas ligand in the active suppression of systemic immune responses by ultraviolet radiation. J Exp Med 1999; 189(8):1285-1294.
35. Toews GB, Bergstresser PR, Streilein J W. Langerhans cells: sentinels of skin associated lymphoid tissue. J Invest Dermatol 1980; 75(l):78-82.
36. Simon JC, Cruz PD, Jr, Bergstresser PR et al. Low dose ultraviolet B-irradiated Langerhans cells preferentially activate CD4 cells of the T helper 2 subset. J Immunol 1990; 145(7):2087-2091.
37. Araneo BA, Dowell T, Moon HB et al. Regulation of murine lymphokine production in vivo. Ultraviolet radiation exposure depresses IL-2 and enhances IL-4 production by T-cells through an IL-1-dependent mechanism. J Immunol 1989; 143(6): 1737-1744.
38. Beissert S, Ruhlemann D, Mohammad T et al. IL-12 prevents the inhibitory effects of cis-urocanic acid on tumor antigen presentation by Langerhans cells: implications for photocarcinogenesis. J Immunol 2001; 167(11):6232-6238.
39. Hart PH, Jaksic A, Swift G et al. Histamine involvement in UVB- and cis-urocanic acid-induced systemic suppression of contact hypersensitivity responses. Immunology 1997; 91(4):601-608.
40. Hart PH, Grimbaldeston MA, Swift GJ et al. Dermal mast cells determine susceptibility to ultraviolet B-induced systemic suppression of contact hypersensitivity responses in mice. J Exp Med 1998; 187(12):2045-2053.
41. Khalil Z, Townley SL, Grimbaldeston MA et al. cis-Urocanic acid stimulates neuropeptide release from peripheral sensory nerves. J Invest Dermatol 2001; 117(4):886-891.
42. Grimbaldeston MA, Skov L, Finlay-Jones JJ et al. Increased dermal mast cell prevalence and susceptibility to development of basal cell carcinoma in humans. Methods 2002; 28(l):90-96.
43. Piccinni MP, Maggi E, Romagnani S. Environmental factors favoring the allergen-specific 1h2 response in allergic subjects. Ann NY Acad Sci 2000; 917:844-852.
44. Kameyoshi Y, Morita E, Tanaka T et al. Interleukin-1 alpha enhances mast cell growth by a fibroblast-dependent mechanism. Arch Dermatol Res 2000; 292(5) :240-247.
45. Grimbaldeston MA, Skov L, Baadsgaard O et al. Communications: high dermal mast ceU prevalence is a predisposing factor for basal cell carcinoma in humans. J Invest Dermatol 2000; 115(2):317-320.
46. Ziegler A, Leflfell DJ, Kunala S et al. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci USA 1993; 90(9) :4216-4220.
47. Schwarz T. Mechanisms of UV-induced immunosuppression. Link between UV-induced tolerance and apoptosis. Eur J Dermatol 1998; 8(3):196-197.
48. Byrne SN, Spinks N, Halliday GM. The induction of immunity to a protein antigen using an adjuvant is significantly compromised by ultraviolet A radiation. J Photochem Photobiol B 2006; 84(2): 128-134.
49. Schiller M, Metze D, Lugcr TA et al. Immune response modifiers-mode of action. Exp Dermatol 2006; 15(5):331-341.
50. Hung K, Hayashi R, Lafond-Walker A et al. The central role of CD4() T-cells in the antitumor immune response. J Exp Med 1998; 188(12):2357-2368.
51. Harrell MI, Iritani BM, Ruddell A. Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. Am J Pathol 2007; 170(2) :774-786.
52. Poland A, Palen D, Glover E. Tumour promotion by TCDD in skin of HRS/J hairless mice. Nature 1982; 300(5889):271-273.
53. Guiducci C, Valzasina B, DisUch H et al. CD40/CD40L interaction regulates CD4 CD25 T-reg homeostasis through dendritic cell-produced IL-2. Eur J Immunol 2005; 35(2):557-567.
54. Moore KW, de Waal Malefyt R, Coflnan RL et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765.
55. Mueller MM. Inflammation in epithehal skin tumours: old stories and new ideas. Eur J Cancer 2006; 42(6):735-744.
56. Wang T, Niu G, Kortylewski M et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004; 10(l):48-54.
57. Farnoush A, Mackenzie IC. Sequential histological changes and mast cell response in skin during chemically-induced carcinogenesis. J Oral Pathol 1983; 12(4):300-306.
58. Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol 1996; 3(ll):895-904.
59. Coussens LM, Tinkle CL, Hanahan D et al. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000; 103(3) :481-490.
60. Trinchicri G. Biology of natural killer cells. Adv Immunol 1989; 47:187-376.
61. Smyth MJ, Thia KY, Cretney E et al. Perforin is a major contributor to NK-cell control of tumor metastasis. J Immunol 1999; 162(11):6658-6662.
62. Hayakawa Y, Kelly JM, Westwood JA et al. Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J Immunol 2002; 169(10):5377-5381.
63. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and inmiunotherapy. Nat Immunol 2001; 2(4):293-299.
64. Paul P, Rouas-Freiss N, Khalil-Daher I et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 1998; 95(8):4510-4515.
65. Caux C, Massacrier C, Dezutter-Dambuyant C et al. Human dendritic Langerhans cells generated in vitro from CD34 progenitors can prime naive CD4 T-cells and process soluble antigen. J Immunol 1995; 155(11):5427-5435.
66. Katz SI, Tamaki K, Sachs DH. Epidermal Langerhans cells are derived from cells originating in bone marrow. Nature 1979; 282(5736) :324-326.
67. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004; 104(8):2235-2246.
68. Kripke ML. Effects of UV radiation on tumor immunity. J Natl Cancer Inst 1990; 82(17):1392-1396.
69. Banchereau J, Steinman RM. Dendritic cells and the control of immunity Nature 1998; 392(6673) :245-252.
70. Figdor CG, de Vries IJ, Lesterhuis WJ et al. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10(5):475-480.
71. Stene MA, Babajanians M, Bhuta S et al. Qiiantitative alterations in cutaneous Langerhans cells during the evolution of malignant melanoma of the skin. J Invest Dermatol 1988; 91(2):125-128.
72. Ladanyi A, Kiss J, Somlai B et al. Density of DC-LAMP() mature dendritic cells in combination with activated T-lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 2007.
73. Mellor AL, Keskin DB, Johnson T et al. Cells expressing indoleamine 2,3-dioxygenase inhibit T-cell responses. J Immunol 2002; 168(8):3771-3776.
74. Munn DH, Zhou M, Attwood JT et al. Prevention of allogeneic fetal rejection by tryptophan cataboUsm. Science 1998; 281(5380):1191-1193.
75. Munn DH, Shafizadch E, Attwood JT et al. Inhibition of T-ccll proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189(9):1363-1372.
76. Munn DH, Sharma MD, Lee JR et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002; 297(5588): 1867-1870.
77. van Oijen M, Bins A, Elias S et al. On the role of melanoma-specific CD8 T-ccll immunity in disease progression of advanced-stage melanoma patients. Clin Cancer Res 2004; 10(l4):4754-4760.
78. Boczkowski D, Nair SK, Nam JH ct al. Induction of tumor immunity and cytotoxic T-lymphocytc responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000; 60(4):1028-1034.
79. Anichini A, Mortarini R, Maccalli C ct al. Cytotoxic T-cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J Immunol 1996; 156(1):208-217.
80. Grifiioen M, Kessler JH, Borghi M et al. Detection and functional analysis of CD8 T-cells specific for FRAME: a target for T-cell therapy Clin Cancer Res 2006; 12(10):3130-3136.
81. McWilliams JA, McGurran SM, Dow SW et al. A modified tyrosinase-related protein 2 epitope generates high-afiinity tumor-specific T-cells but does not mediate therapeutic efficacy in an intradermal tumor model. J Immunol 2006; 177(1):155-161.
82. Bennink JR anderson R, Bacik I et al. Antigen processing: where tumor-specific T-cell responses begin. J Immunothcr 1993; l4(3):202-208.
83. Konjevic G, Mirjacic Martinovic K, Vuletic A et al. Low expression of CD 161 and NKG2D activating NK receptor is associated with impaired NK-cell cytotoxicity in metastatic melanoma patients. Clin Exp Metastasis 2007.
84. Lee TH, Cho YH, Lee MG. Larger numbers of immature dendritic cells augment an antitumor effect against established murine melanoma cells. Biotechnol Lett 2007; 29(3):351-357.
85. Brunda MJ, Gately MK. Antitumor activity of interleukin-12. Clin Immunol Immunopathol 1994; 71(3):253-255.
86. Nghiem DX, Kazimi N, Mitchell DL et al. Mechanisms underlying the suppression of established immune responses by ultraviolet radiation. J Invest Dermatol 2002; 119(3):600-608.
87. Bnmda MJ, Luistro L, Warrier RR et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178(4): 1223-1230.
88. Germann T, Rude E, Schmitt E. The influence of IL12 on the development of Thl and 1h2 cells and its adjuvant effect for humoral immune responses. Res Immunol 1995; 146(7-8) :481-486.
89. Macda A, Schneider SW, Kojima M et al. Enhanced photocarcinogenesis in interleukin-12-deficient mice. Cancer Res 2006; 66(6) :2962-2969.
90. Baron S, Hernandez J, Bekisz J et al. Clinical model: interferons activate human monocytes to an eradicative tumor cell level in vitro. J Interferon Cytokine Res 2007; 27(2): 157-164.
91. Billiau A. Intcrferon-gamma: biology and role in pathogenesis. Adv Immunol 1996; 62:61-130.
92. Moore RJ, Owens DM, Stamp G et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999; 5(7):828-831.
93. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T-cell functions during tumor evasion of immune surveillance. Cancer Cell 2005; 8(5):369-380.
94. Kooy AJ, Prens EP, Van Heukelum A et al. Interferon-gamma-induced ICAM-1 and CD40 expression, complete lack of HLA-DR and CD80 (B7.1) and inconsistent HLA-ABC expression in basal cell carcinoma: a possible role for interleukin-10? J Pathol 1999; 187(3):351-357.
95. Kooy AJ, Tank B, Vuzevski VD et al. Expression of intcrferon-gamma receptors and interferon-gamma-induced up-regulation of intercellular adhesion molecule-1 in basal cell carcinoma; decreased expression of IFN-gamma R and shedding of ICAM-1 as a means to escape immune surveillance. J Pathol 1998; 184(2):169-176.
96. Mouawad R, Rixe O, Meric JB et al. Serimi interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study Cytokines Cell Mol Ther 2002; 7(4):151-156.
97. Jee SH, Shen SC, Chiu HC et al. Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency. Oncogene 2001; 20(2): 198-208.
98. Biggs MW, Eiselein JE. Suppression of immune surveillance in melanoma. Med Hypotheses 2001; 56(6):648-652.
99. Ijland SA, Jager MJ, Heijdra BM ct al. Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines. Melanoma Res 1999; 9(5):445-450.
100. Redondo P, Sanchez-Carpintero I, Bauza A et al. Immunologic escape and angiogenesis in human malignant melanoma. J Am Acad Dermatol 2003; 49(2):255-263.
101. Ugurel S, Rappl G, Tilgen W ct aL Increased serum concentration of angiogenic factors in maUgnant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001; 19(2):577-583.
102. Kim J, Modlin RL, Moy RL et al. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T-cell immune response. J Immunol 1995; 155(4):2240-2247.
103. Guiducci C, Vicari AP, Sangaletti S et al. Redirecting in vivo eUcited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 2005; 65(8):3437-3446.
104. Luft T, JefFord M, Luetjens P et al. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood 2002; 100(4):1362-1372.
105. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001; 29(2): 117-129.
106. Dumont N, Arteaga CL. Targeting the TGF beta signaling network in human neoplasia. Cancer Cell 2003; 3(6):531-536.
107. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998; 67:753-791.
108. Pierce DF Jr, Johnson MD, Matsui Y et al. Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1. Genes Dev 1993; 7(12A):2308-2317.
109. Bottinger EP, Jakubczak JL, Haines DC et al. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7, 12-dimethylbenz-[a]-anthracene. Cancer Res 1997; 57(24):5564-5570.
110. CuiW , Fowlis DJ, Bryson S et al. TGFbetal inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 1996; 86(4):531-542.
111. Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2002; 2(l):46-53.
112. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001; 29(2): 117-129.
113. McKarns SC, Schwartz RH, Kaminski NE. Smad3 is essential for TGF-beta 1 to suppress IL-2 production and TCR-induced proliferation, but not IL-2-induced proliferation. J Immunol 2004; 172(7):4275-4284.
114. McCarter M, Clarke J, Richter D et al. Melanoma skews dendritic cells to facilitate a T helper 2 profile. Surgery 2005; 138(2):321-328.
115. Hermans IF, Silk JD, Gileadi U et al. NKT cells enhance CD4 and CD8 T-cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immimol 2003; 171 (10):5140-5147.
116. Pulendran B. Modulating TH1/TH2 responses with microbes, dendritic cells and pathogen recognition receptors. Immunol Res 2004; 29(1-3): 187-196.
117. Lauerova L, Dusek L, Simickova M et al. Malignant melanoma associates with Thl/1h2 imbalance that coincides with disease progression and immunotherapy response. Neoplasma 2002; 49(3): 159-166.
118. Girardi M, Oppenheim DE, Steele CR et al. Regulation of cutaneous malignancy by gammadelta T-cells. Science 2001; 294(5542):605-609.
119. Tefany FJ, Bametson RS, Halliday GM et al. Immunocytochemical analysis of the cellular infiltrate in primary regressing and nonregressing malignant melanoma. J Invest Dermatol 1991; 97(2): 197-202.
120. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995; 16(10) :487-494.
121. Garrido F, Ruiz-Cabello F, Cabrera T et al. Implications for immunosurveillancc of altered HLA class I phenotypes in human tumours. Immunol Today 1997; 18(2):89-95.
122. Chen C, Nabavi N. In vitro induction of T-cell anergy by blocking B7 and early T-cell costimulatory molecule ETC-1/B7-2. Immunity 1994; 1(2):147-154.
123. Valenti R, Huber V, Filipazzi P et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T-lymphocytes. Cancer Res 2006; 66(18):9290-9298.
124. Parmiani G, Castelli C, Santinami M et al. Melanoma immunology: past, present and future. Curr Opin Oncol 2007; 19(2):121-127.
125. Rosenberg SA, Sherry RM, Morton KE et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8 T-cells in patients with melanoma. J Immunol 2005; 175(9):6169-6176.
126. Mortarini R, Piris A, Maurichi A et al. Lack of terminally differentiated tumor-specific CD8 T-cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res 2003; 63(10):2535-2545.
127. Lengagnc R, Le Gal FA, Garcette M et al. Spontaneous vitiligo in an animal model for human melanoma: role of tumor-specific CD8 T-cells. Cancer Res 2004; 64(4): 1496-1501.
128. Pardoll DM, Topalian SL. The role of CD4 T-cell responses in antitumor immunity. Curr Opin Immunol 1998; 10(5):588-594.
129. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005; 437(7055): 141-146.
130. Turk MJ, Guevara-Patino JA, Rizzuto GA et al. Concomitant tumor immunity to a poorly immimogenic melanoma is prevented by regulatory T-cells. J Exp Med 2004; 200(6) :771-782.
131. Abbas AK. Die and let live: eliminating dangerous lymphocytes. Cell 1996; 84(5):655-657.
132. Walker PR, Saas P, Dietrich PY. Role of Fas ligand (CD95L) in immmie escape: the tumor cell strikes back. J Immunol 1997; 158(10):4521-4524.
133. Hahne M, Rimoldi D, Schroter M et al. Melanoma cell expression of Fas(Apo-l/CD95) ligand: implications for tumor immune escape. Science 1996; 274(5291): 1363-1366.
134. Rivoltini L, Radrizzani M, Accornero P et al. Human melanoma-reactive CD4 and CD8 CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. J Immunol 1998; 161(3):1220-1230.
135. Dong H, Zhu G, Tamada K et al. B7-H1, a third member of the B7 family, costimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5(12): 1365-1369.
136. Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8(8):793-800.
137. Iwai Y, Ishida M, Tanaka Y et al. Involvement of PD-Ll on tumor cells in the escape from host immune system and tumor immunotherapy by PD-Ll blockade. Proc Natl Acad Sci USA 2002; 99(19):12293-12297.
138. Strome SE, Dong H, Tamura H et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003; 63(19):6501-6505.
139. Tamura H, Dong H, Zhu G et al. B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood 2001; 97(6): 1809-1816.
140. Standcr S, Schwarz T. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is expressed in normal skin and cutaneous inflammatory diseases, but not in chronically UV-exposed skin and nonmelanoma skin cancer. Am J Dermatopathol 2005; 27(2): 116-121.
141. Chebassier N, Leroy S, Tenaud I et al. Overeiqpression of MMP-2 and MMP-9 in squamous cell carcinomas of immunosuppressed patients. Arch Dermatol Res 2002; 294(3): 124-126.
142. Guo J, Zhu J, Shcng X et al. Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitimior effect in patients with advanced melanoma. Int J Cancer 2007.
143. Ribas A. Update on immunotherapy for melanoma. J Natl Compr Cane Netw 2006; 4(7):687-694.
144. Wigginton JM, Gruys E, Geiselhart L et al. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 2001; 108(l):51-62.
145. Lucas ML, Heller R. IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma. DNA Cell Biol 2003; 22(12):755-763.
146. Marshall JA, Forster TH, Purdie DM et al. Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma. Immunol Cell Biol 2006; 84(3):295-302.
147. Kono M, Dimn IS, Durda PJ et al. Role of the mitogcn-activatcd protein kinase signaling pathway in the regulation of human melanocytic antigen expression. Mol Cancer Res 2006; 4(10):779-792.
148. Schuler G, Schuler-lhurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003; 15(2): 138-147.
149. Tormo D, Ferrer A, Bosch P et al. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. Cancer Res 2006; 66( 10):5427-5435.